Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ cost-effectiveness agenda

This article was originally published in The Gray Sheet

Executive Summary

Initial priority list should be directed toward prescription drug comparative clinical effectiveness in expectation of the Medicare Rx benefit, according to an 1April 23 Federal Register notice. The agency notes, however, that other "health care items and services" will be considered for the FY 2006 list. Device stakeholders have been monitoring the Agency for Healthcare Research & Quality closely to determine whether devices will be subject to cost-effectiveness research under the Medicare Modernization Act provision (2"The Gray Sheet" April 12, 2004, p. 10). Proposed research items must be received by May 7 and July 1 for the initial and FY 2006 lists, respectively...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT020098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel